DK2806853T3 - Tidsudløst bionedbrydelige eller bioeroderbare mikrosfærer eller mikropartikler suspenderet i en størknende, depotdannende, injicerbar lægemiddelformulering - Google Patents

Tidsudløst bionedbrydelige eller bioeroderbare mikrosfærer eller mikropartikler suspenderet i en størknende, depotdannende, injicerbar lægemiddelformulering Download PDF

Info

Publication number
DK2806853T3
DK2806853T3 DK13702182.0T DK13702182T DK2806853T3 DK 2806853 T3 DK2806853 T3 DK 2806853T3 DK 13702182 T DK13702182 T DK 13702182T DK 2806853 T3 DK2806853 T3 DK 2806853T3
Authority
DK
Denmark
Prior art keywords
bioerroducable
injective
microspheres
strengthening
depositing
Prior art date
Application number
DK13702182.0T
Other languages
Danish (da)
English (en)
Inventor
David A Marsh
Hongwen Ma Rivers
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2806853T3 publication Critical patent/DK2806853T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK13702182.0T 2012-01-23 2013-01-22 Tidsudløst bionedbrydelige eller bioeroderbare mikrosfærer eller mikropartikler suspenderet i en størknende, depotdannende, injicerbar lægemiddelformulering DK2806853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Publications (1)

Publication Number Publication Date
DK2806853T3 true DK2806853T3 (da) 2020-09-28

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13702182.0T DK2806853T3 (da) 2012-01-23 2013-01-22 Tidsudløst bionedbrydelige eller bioeroderbare mikrosfærer eller mikropartikler suspenderet i en størknende, depotdannende, injicerbar lægemiddelformulering

Country Status (17)

Country Link
US (5) US20130189369A1 (enExample)
EP (1) EP2806853B1 (enExample)
JP (1) JP6282231B2 (enExample)
KR (5) KR20140114892A (enExample)
CN (1) CN104136006B (enExample)
AU (3) AU2013212583A1 (enExample)
BR (1) BR112014017969A8 (enExample)
CA (1) CA2861348C (enExample)
DK (1) DK2806853T3 (enExample)
ES (1) ES2821526T3 (enExample)
HU (1) HUE050904T2 (enExample)
IL (2) IL233620A0 (enExample)
MX (1) MX364864B (enExample)
NZ (1) NZ627368A (enExample)
RU (1) RU2672596C2 (enExample)
WO (1) WO2013112434A1 (enExample)
ZA (1) ZA201405091B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
CN109310680B (zh) * 2016-06-30 2022-11-01 度瑞公司 长效配制物
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
BR112020000506A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4308106A4 (en) * 2021-03-15 2025-02-26 Oakwood Laboratories, Llc MICROSPHERE FORMULATIONS CONTAINING NALTREXONE AND METHODS OF PREPARING AND USING THE SAME
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN116869914A (zh) * 2023-05-30 2023-10-13 庄秉谚 无针注射系统的投递物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP1125577B1 (en) * 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
KR101892745B1 (ko) * 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子

Also Published As

Publication number Publication date
AU2017258895A1 (en) 2017-11-30
CA2861348A1 (en) 2013-08-01
CN104136006A (zh) 2014-11-05
KR20200133286A (ko) 2020-11-26
KR20200073292A (ko) 2020-06-23
US20240423922A1 (en) 2024-12-26
HK1204765A1 (en) 2015-12-04
BR112014017969A8 (pt) 2017-07-11
EP2806853A1 (en) 2014-12-03
NZ627368A (en) 2016-11-25
IL265620B (en) 2022-03-01
ZA201405091B (en) 2015-12-23
CN104136006B (zh) 2017-11-24
MX2014008857A (es) 2015-07-17
AU2019204957A1 (en) 2019-07-25
US20230390212A1 (en) 2023-12-07
US20240226022A1 (en) 2024-07-11
MX364864B (es) 2019-05-09
IL233620A0 (en) 2014-08-31
AU2013212583A1 (en) 2014-08-14
JP6282231B2 (ja) 2018-02-21
RU2014134420A (ru) 2016-03-20
AU2017258895B2 (en) 2019-04-18
KR102183727B1 (ko) 2020-11-27
IL265620A (en) 2019-05-30
HUE050904T2 (hu) 2021-01-28
CA2861348C (en) 2017-07-04
US20130189369A1 (en) 2013-07-25
WO2013112434A1 (en) 2013-08-01
KR20230104761A (ko) 2023-07-10
KR20220044379A (ko) 2022-04-07
US20200297650A1 (en) 2020-09-24
EP2806853B1 (en) 2020-07-08
JP2015504098A (ja) 2015-02-05
BR112014017969A2 (enExample) 2017-06-20
RU2672596C2 (ru) 2018-11-16
KR20140114892A (ko) 2014-09-29
ES2821526T3 (es) 2021-04-26

Similar Documents

Publication Publication Date Title
NL350117I2 (nl) Metrafenon en mefentrifluconazool
IL262651B (en) Microparticles of polymeric proteins
IL236838B (en) Anti-dengue virus antibodies and uses thereof
IL232780A0 (en) Influenza virus vaccines and uses thereof
IL231547A0 (en) Influenza virus vaccines and uses thereof
EP2912805A4 (en) NETWORK VIRTUALIZATION VIA INFINIBAND
EP2926266A4 (en) CLOUD OBJECT
PL2826467T3 (pl) Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PL2976946T3 (pl) Kompozycje cyklodekstryny, wyroby i sposoby
ME03079B (me) Ligandi modifikovani cirkularnom permutacijom као agonisтi i antagonisti
DK3505751T3 (da) Vindmøllevinger
BR112014028725A2 (pt) artigo adesivo, construções adesivas e métodos para preparar uma construção adesiva
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
EP2910592A4 (en) POLYMERIZABLE COMPOSITION AND HARDENED ARTICLE
FR2985500B1 (fr) Configuration d'helicoptere
EP2905304A4 (en) CODED POLYMERMIC PARTICLES
BR112014027026A2 (pt) aerofólio
UA24750S (uk) Пляшка
HRP20181276T1 (hr) Konjugat fotosenzibilizatora s hitozanom i njegova upotreba
EP2905840A4 (en) REFLECTION ARRANGEMENT
EP2882036A4 (en) REFLECTION ARRANGEMENT
LT2825565T (lt) Katijoninis polimeras glikogeno pagrindu
PL2917011T3 (pl) Preforma i pojemnik
PT2623096T (pt) Composição farmacêutica com libertação prolongada de trimetazidina
PL2858830T3 (pl) Koło wielokierunkowe